Alejandro González Veliz/LinkedIn
Jun 23, 2026, 09:36
Alejandro González Veliz: Key Takeaways from the 2026 ACC/AHA Dyslipidemia Guidelines
Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn:
“Dyslipidemia management is entering a new era.
The 2026 ACC/AHA Guideline moves beyond LDL-C alone and embraces a more personalized approach to cardiovascular prevention.
- LDL-C goals are back
- Lp(a) should be measured at least once
- ApoB helps uncover residual risk
- Coronary calcium refines risk assessment
- Earlier intervention may change lifelong outcomes
The message is simple: identify risk earlier, treat smarter, and prevent ASCVD before the first event occurs.
Which update do you think will have the greatest impact on your daily practice?
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 19:00Caitlin Raymond: Can Artificial Blood Solve Blood Supply Shortages?
-
Sep 29, 2026, 18:51Chaza Alaji: Dyslipidemia, Thrombosis and the DIC Diagnostic Trap
-
Sep 29, 2026, 17:31Rajnikant Patel: Bridging Ayurvedic Concepts and Modern Toxin-Mediated Disease
-
Sep 29, 2026, 17:13Nicholas Lang։ A Meaningful Case of Immune Thrombocytopenia
-
Sep 29, 2026, 16:55Ayatullah Gamal Wahab: When the CBC Lies
-
Sep 29, 2026, 16:35Jonathan Douxfils: Navigating the VTE Risk Continuum in Reproductive Medicine
-
Sep 29, 2026, 16:35Chaima Rajeh: Types of Anemia and Their Laboratory Features
-
Sep 29, 2026, 16:27Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge